Risk factors

Savara relies entirely on the clinical, regulatory, and commercial success of its sole product candidate, MOLBREEVI, for aPAP. The company faces significant risks regarding capital requirements, regulatory approvals, third-party reimbursement, and lack of issued patents for MOLBREEVI.

Operating losses of $1.7 million in 2024 and $1.6 million in 2023 drive financing and profitability concerns. Seventy percent of net revenue depends on five key customers including Northrop Grumman and Detroit Diesel. Fixed-price contracts and single-source material dependencies expose the business to margin compression and supply shocks.

TAO Synergies faces high reliance on its lead drug Bryostatin-1, which failed its primary Phase 2 endpoint.

TIC Solutions faces heavy reliance on volatile oil, gas, and industrial markets for its asset integrity services. Operations carry severe physical and safety risks due to hazardous environments and Rope Access Techniques. The company maintains substantial debt leverage totaling over $800 million under its credit facilities.

Deep-sea nodule collection faces severe regulatory uncertainty under the ISA, UNCLOS, and potential U.S. DSHMRA pathways. Commercial viability is unproven, relying heavily on Allseas and unbuilt equipment. Environmental opposition and potential biodiversity impacts threaten market acceptance in the EV supply chain.

Tempest Therapeutics faces primary risks from its heavy reliance on two unapproved lead product candidates, amezalpat and TPST-1495. The company requires significant ongoing capital and debt financing, pledging all assets including intellectual property to Oxford Finance. Clinical development, trial patient enrollment, and third-party manufacturing dependencies present continuous operational threats.

Concentration on Bloomia cut tulips business dominates company risks and financing constraints.

The risk profile is dominated by dependence on key insurance carriers like The Progressive Corporation, heavy geographic concentration in Texas, California, and Louisiana, and exposure to interest rate fluctuations.

The company operates strictly as a royalty-dependent business following the Mayne Transaction, relying on third-party licensees for product sales.

Clinical stage biopharmaceutical company with no approved products focused on developing novel precision therapies using the SNÅP platform. Relies heavily on third-party manufacturers, clinical trial sites, and companion diagnostic partners. Faces substantial ongoing capital requirements with cash runway projected through at least 2027.

Growth depends on new store openings, e-commerce execution, and managing inventory shrink from organized retail crime.

The risk factors are dominated by the recent acquisitions of Fat Shark and Rotor Riot, ongoing negative cash flows, reliance on Chinese component imports, and the pending $14.5 million Aloft merger.